COMMUNIQUÉS West-GlobeNewswire

Devenez membre PREMIUM

Accèdez sans limite aux 15 000 actualités du site
et recevez gratuitement chaque semaine,
la Newsletter Santé log avec les actus Santé à ne pas manquer !

S'abonner
29€ TTC/an

Je suis déjà membre PREMIUM

Se connecter

Scienture Holdings, Inc. Issues Annual Letter to Shareholders
03/04/2025 - 14:26
TAMPA, FL, April 03, 2025 (GLOBE NEWSWIRE) -- SCIENTURE HOLDINGS, INC. (NASDAQ: SCNX) a holding company for existing and planned pharmaceutical operating companies focused on providing enhanced value to patients, [...]
Autonomix Medical, Inc. to Highlight Technology and Early Proof-of-Concept Study Results in a Poster Presentation at the 2025 European Conference on Interventional Oncology (ECIO)
03/04/2025 - 14:30
THE WOODLANDS, TX, April 03, 2025 (GLOBE NEWSWIRE) -- Autonomix Medical, Inc. (NASDAQ: AMIX) (“Autonomix” or the “Company”), a medical device company focused on advancing precision nerve-targeted treatments, today [...]
NewGen Secures Strategic Funding to Drive International Expansion and Corporate Growth
03/04/2025 - 14:30
Initial focus includes NewGen’s expansion into UAE, with further growth initiatives to follow BANGKOK, April 03, 2025 (GLOBE NEWSWIRE) -- NewGenIvf Group Limited (NASDAQ: NIVF) (“NewGen” or the “Company”), a [...]
Globus Medical completes acquisition of Nevro Corp.
03/04/2025 - 14:31
AUDUBON, Pa., April 03, 2025 (GLOBE NEWSWIRE) -- Globus Medical, Inc. (NYSE: GMED), a leading musculoskeletal technology company, today announced the completion of its previously disclosed acquisition of Nevro Corp., a [...]
Winstrol Steroids: Winstrol Benefits, Winstrol Side Effects, Winstrol Results & Buy Winstrol Pills Alternatives Win-Max By CrazyBulk
03/04/2025 - 14:33
NEW YORK, April 03, 2025 (GLOBE NEWSWIRE) -- “We’ve got several pro bodybuilding athletes ready and waiting to get to know you in our free private CrazyBulk community. And you’ll receive an invite to it the minute you [...]
Boehringer Ingelheim strengthens antibody-drug conjugate portfolio with new NBE Therapeutics R&D center in Basel
03/04/2025 - 09:00
CHF 27 million i nvestment signi ficantly bolsters Boehringer's ADC portfolio, driven by its subsidiary, NBE Therapeutics, to achieve the company’s aim of transforming the lives of people with cancer . Boehringer [...]
Prime Biome: We Tested It—Here’s My Honest Prime Biome Review After 117 Days!
03/04/2025 - 10:35
Is Prime Biome’s “gut-skin synergy” the secret to beating bloating, revealing clearer skin, and maintaining steady weight management? Explore real reviews and where to buy. ST. PETERSBURG, Fla., April 03, 2025 (GLOBE [...]
Arialief: We Tested It—Here’s Our Honest Arialief Review “Shocking Conclusion”
03/04/2025 - 10:54
Is Arialief the breakthrough for nerve pain, numbness, and tingling through full-spectrum metabolic support? Read our real Arialief review and discover where to buy it online AURORA, Colo., April 03, 2025 (GLOBE [...]
Veteran Banker Joins Avextra’s Supervisory Board
03/04/2025 - 07:00
News Release Dr. Stefan Jentzsch, Partner at the global investment firm Perella Weinberg Partners has been appointed to Avextra’s Supervisory Board, bringing decades of experience in corporate finance, M&A, and [...]
Pharming Group announces the filing of its 2024 Annual Report and Form 20-F
03/04/2025 - 07:00
Leiden, the Netherlands, April 3, 2025: Pharming Group N.V. (“Pharming” or “the Company”) (Euronext Amsterdam: PHARM / Nasdaq: PHAR) announces the filing of its Annual Report for the year ended December 31, 2024 (the “ [...]
Communiqué de presse : Le rilzabrutinib obtient la désignation de médicament orphelin aux États-Unis pour le traitement de deux maladies rares contre lesquelles il n’existe aucun médicament approuvé
03/04/2025 - 07:00
Le rilzabrutinib obtient la désignation de médicament orphelin aux États-Unis pour le traitement de deux maladies rares contre lesquelles il n’existe aucun médicament approuvé Désignation accordée pour l’anémie [...]
Press Release: Rilzabrutinib granted orphan drug designation in the US for two rare diseases with no approved medicines
03/04/2025 - 07:00
Rilzabrutinib granted orphan drug designation in the US for two rare diseases with no approved medicines Designation granted for warm autoimmune hemolytic anemia and IgG4-related disease Rilzabrutinib is currently under [...]
Informations relatives au nombre total de droits de vote et d’actions composant le capital
03/04/2025 - 08:00
Informations relatives au nombre total de droits de vote et d’actions composant le capital Nantes, le 3 avril 2025 – En application de l’article L. 233-8 II du Code de commerce et de l’article 223-16 du Règlement [...]
LIfT BioSciences gains access to half a million allogeneic donors through collaboration with Gift of Life Biologics
03/04/2025 - 08:00
Press release LIfT BioSciences gains access to half a million allogeneic donors through collaboration with Gift of Life Biologics Access to extensive donor pool supports LIfT’s move into the clinic London, 03 April 2025 [...]
Novo Nordisk announces changes in Executive Management
03/04/2025 - 08:00
Bagsværd, Denmark, 3 April 2025 – Novo Nordisk today announced the following changes in Executive Management. After a distinguished career of 28 years with Novo Nordisk, hereof seven years as executive vice president of [...]
FibroBiologics annonce des progrès scientifiques suite à la confirmation des résultats relatifs à la réparation de tissus cérébraux
03/04/2025 - 04:33
HOUSTON, 03 avr. 2025 (GLOBE NEWSWIRE) -- FibroBiologics, Inc. (Nasdaq : FBLG), ou « FibroBiologics », une société de biotechnologie au stade clinique détenant plus de 240 brevets délivrés et en instance portant sur le [...]
Mesoblast Files Request for Type B Meeting with FDA to Discuss Accelerated Approval Pathway for Revascor® in Ischemic Heart Failure
03/04/2025 - 01:15
NEW YORK, April 02, 2025 (GLOBE NEWSWIRE) -- Mesoblast (Nasdaq:MESO; ASX:MSB), global leader in allogeneic cellular medicines for inflammatory diseases, today provided an update on its plans to meet with the United [...]
RxSight, Inc. Announces Preliminary First Quarter 2025 Revenue and Revised 2025 Guidance
03/04/2025 - 02:00
ALISO VIEJO, Calif., April 02, 2025 (GLOBE NEWSWIRE) -- (NASDAQ: RXST) – RxSight, Inc., an ophthalmic medical device company dedicated to providing high-quality customized vision to patients following cataract surgery, [...]
Novartis receives FDA accelerated approval for Vanrafia® (atrasentan), the first and only selective endothelin A receptor antagonist for proteinuria reduction in primary IgA nephropathy (IgAN)
03/04/2025 - 02:13
Ad hoc announcement pursuant to Art. 53 LR Vanrafia can be seamlessly added to supportive care in IgAN and used as a foundational therapy with no requirement for a REMS (Risk Evaluation Mitigation Strategy) program 1 [...]

Pages